Released Mar 27, 2025, before the open
10-K filed Mar 27, 2025, 86 days after period end · 0001576885-25-000049
Q4 2024 · 10-K
derived · Computed from the longer spans the company filed.
Revenue—
Net Income-$37.15M-$37.15M derivedN/M vs Q4 2023N/M vs Q3 2024
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$39,597,000N/M
Operating Cash Flowderived-$27,215,000N/M
Free Cash Flowderived-$27,215,000N/M
What the release said
The release
Same quarter
| Metric | Q4 2024dderived from reported figures | Q4 2023dderived from reported figures | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures |
|---|---|---|---|---|
| Net Income | -$37.15M | -$16.50M | -$12.87M | -$8.35M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Acumen Pharmaceuticals, Inc. · CIK 1576885 · Engraved from SEC EDGAR